Shopping Cart 0
Cart Subtotal
USD 0

Lassa Fever (Lassa Hemorrhagic Fever)-Pipeline Review, H2 2017

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
USD 2000

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
USD 4000

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
USD 6000
  • Details
  • Table Of Content
  • Licence Rights
  • Section Purchase
  • Products and Companies

Details

Lassa Fever (Lassa Hemorrhagic Fever)-Pipeline Review, H2 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Lassa Fever-Pipeline Review, H2 2017, provides an overview of the Lassa Fever (Infectious Disease) pipeline landscape.

Lassa fever is an acute viral hemorrhagic illness caused by Lassa virus, a member of the arenavirus family of viruses. It is transmitted to humans from contacts with food or household items contaminated with rodent excreta. Symptoms include fever, headache, chills, back pain, weight loss, swollen neck, rashes and bleeding.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Lassa Fever-Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Lassa Fever (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Lassa Fever (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Lassa Fever (Lassa Hemorrhagic Fever) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Preclinical and Discovery stages are 10 and 5 respectively. Similarly, the Universities portfolio in Discovery stages comprises 1 molecules, respectively.

Lassa Fever (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

The pipeline guide provides a snapshot of the global therapeutic landscape of Lassa Fever (Infectious Disease).

The pipeline guide reviews pipeline therapeutics for Lassa Fever (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Lassa Fever (Infectious Disease) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Lassa Fever (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Lassa Fever (Infectious Disease)

Reasons to buy

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Lassa Fever (Infectious Disease).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Lassa Fever (Infectious Disease) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

READ MORE

Table Of Content

Scope

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Lassa Fever (Lassa Hemorrhagic Fever)-Overview

Lassa Fever (Lassa Hemorrhagic Fever)-Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Lassa Fever (Lassa Hemorrhagic Fever)-Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Lassa Fever (Lassa Hemorrhagic Fever)-Companies Involved in Therapeutics Development

Arno Therapeutics Inc

Celgene Corp

Etubics Corp

Fab'entech SA

GeoVax Labs Inc

Kineta Inc

Profectus BioSciences Inc

Theravectys SA

Lassa Fever (Lassa Hemorrhagic Fever)-Drug Profiles

AR-12-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CC-11050-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

FBH-003-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GEOLM-01-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

infectious disease vaccine-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

KIN-1400-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

lassa fever vaccine-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

lassa fever vaccine-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

lassa fever vaccine-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

lassa fever vaccine-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

LHF-535-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ML-29-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Monoclonal Antibodies for Lassa Fever-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules for Lassa Fever-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit NPC1 for Ebola and Lassa Fever Virus-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ST-193-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Lassa Fever (Lassa Hemorrhagic Fever)-Dormant Projects

Lassa Fever (Lassa Hemorrhagic Fever)-Product Development Milestones

Featured News & Press Releases

Jul 24, 2017: GeoVax Joins with Scripps Research Institute and Institute of Human Virology at University of Maryland School of Medicine to Develop Lassa Fever Vaccine

Jul 11, 2017: Tulane University awarded $12 million to create Lassa vaccine and treatment

May 05, 2016: Kineta Receives Wellcome Trust Award to Advance Novel Therapeutic for Lassa Fever into Clinical Trials

Apr 22, 2016: Kineta Presents Promising New Data on Novel Lassa Fever Antiviral and Broad Spectrum Innate Immune Antivirals

May 28, 2015: Arno Therapeutics Announces AR-12 Antiviral Data Against Multiple Hemorrhagic Fevers Published Online in Antiviral Research

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer


List Of Figure

List of Figures

Number of Products under Development for Lassa Fever (Lassa Hemorrhagic Fever), H2 2017

Number of Products under Development by Companies, H2 2017

Number of Products by Targets, H2 2017

Number of Products by Stage and Targets, H2 2017

Number of Products by Mechanism of Actions, H2 2017

Number of Products by Stage and Mechanism of Actions, H2 2017

Number of Products by Routes of Administration, H2 2017

Number of Products by Stage and Routes of Administration, H2 2017

Number of Products by Molecule Types, H2 2017

Number of Products by Stage and Molecule Types, H2 2017


List Of Table

List of Tables

Number of Products under Development for Lassa Fever (Lassa Hemorrhagic Fever), H2 2017

Number of Products under Development by Companies, H2 2017

Number of Products under Development by Universities/Institutes, H2 2017

Products under Development by Companies, H2 2017

Products under Development by Universities/Institutes, H2 2017

Number of Products by Stage and Target, H2 2017

Number of Products by Stage and Mechanism of Action, H2 2017

Number of Products by Stage and Route of Administration, H2 2017

Number of Products by Stage and Molecule Type, H2 2017

Lassa Fever (Lassa Hemorrhagic Fever)-Pipeline by Arno Therapeutics Inc, H2 2017

Lassa Fever (Lassa Hemorrhagic Fever)-Pipeline by Celgene Corp, H2 2017

Lassa Fever (Lassa Hemorrhagic Fever)-Pipeline by Etubics Corp, H2 2017

Lassa Fever (Lassa Hemorrhagic Fever)-Pipeline by Fab'entech SA, H2 2017

Lassa Fever (Lassa Hemorrhagic Fever)-Pipeline by GeoVax Labs Inc, H2 2017

Lassa Fever (Lassa Hemorrhagic Fever)-Pipeline by Kineta Inc, H2 2017

Lassa Fever (Lassa Hemorrhagic Fever)-Pipeline by Profectus BioSciences Inc, H2 2017

Lassa Fever (Lassa Hemorrhagic Fever)-Pipeline by Theravectys SA, H2 2017

Lassa Fever (Lassa Hemorrhagic Fever)-Dormant Projects, H2 2017

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License: 
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:  
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products and Companies

Products

Lassa Fever (Lassa Hemorrhagic Fever) Therapeutic Products under Development, Key Players in Lassa Fever (Lassa Hemorrhagic Fever) Therapeutics, Lassa Fever (Lassa Hemorrhagic Fever) Pipeline Overview, Lassa Fever (Lassa Hemorrhagic Fever) Pipeline, Lassa Fever (Lassa Hemorrhagic Fever) Pipeline Assessment


Companies

Arno Therapeutics Inc

Celgene Corp

Etubics Corp

Fab'entech SA

GeoVax Labs Inc

Kineta Inc

Profectus BioSciences Inc

Theravectys SA